Publications by authors named "R H Dretler"
Treatment of HIV has historically required taking daily oral antiretroviral therapy (ART). A recent alternative to daily oral ART is long-acting injectable ART with cabotegravir plus rilpivirine, administered monthly or every 2 months. The purpose of this qualitative study was to evaluate the concept relevance and interpretability of five previously developed questions: one treatment preference question and four questions designed to assess how the emotional burden associated with HIV treatment impacts treatment preferences.
View Article and Find Full Text PDFArticle Synopsis
- Cabotegravir plus rilpivirine is the only approved long-acting treatment for HIV-1, administered every 2 months, and the SOLAR study compares its effectiveness to daily oral therapy with bictegravir, emtricitabine, and tenofovir alafenamide.
- This phase 3b study involved 687 participants across 118 centers in 14 countries and aimed to assess if the long-acting regimen could maintain HIV virological suppression similarly to the daily regimen.
- The study found that 67% of participants switched to long-acting therapy, demonstrating significant interest in alternatives to daily medications for maintaining HIV suppression.
Kaposi Sarcoma Inflammatory Cytokine Syndrome Presenting as Infection: A Case Report.
J Foot Ankle Surg
January 2021
Kaposi sarcoma inflammatory cytokine syndrome is a rare and fatal malignancy that is challenging to treat. The syndrome appears in individuals who are both human immunodeficiency virus and human herpesvirus 8 positive. The diagnosis of disease is challenging because its presentation mimics sepsis and it has a high mortality rate.
View Article and Find Full Text PDFBackground: Efavirenz (Sustiva®) is used for the treatment of human immunodeficiency virus (HIV) type 1 infection. Hepatoxicity is a known potential adverse drug event with efavirenz; however, to our knowledge, vanishing bile duct syndrome (VBDS), a type of liver injury, has not been reported with this therapy.
Case Presentation: We report the case of a 48-year-old male with HIV and VBDS secondary to antiretroviral therapy.
Background: The safety and efficacy of doravirine were compared with that of efavirenz as initial treatment of adults living with HIV-1 infection (NCT01632345).
Methods: A Phase IIb double-blind trial with participants stratified by screening HIV-1 RNA (≤ or >100,000 copies/ml) and randomized 1:1:1:1:1 to receive once-daily doravirine (25, 50, 100 or 200 mg) or efavirenz 600 mg (Part I) for up to 96 weeks, with open-label tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg (TDF/FTC). After dose selection at week 24, doravirine 100 mg was provided to participants receiving the other doses of doravirine and additional participants were randomized 1:1 to receive once-daily doravirine 100 mg or efavirenz 600 mg for 96 weeks with TDF/FTC (Part II).